MedTrace Logo

A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast Cancer

NCT07180914 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-09-18

No results posted yet for this study

Summary

The goal of this observational study is to observe the long-term prognosis of patients with early HR-positive premenopausal breast cancer. The study also aims to understand the compliance with and reasons for discontinuing adjuvant OFS endocrine therapy under different combination regimens.

The main questions it aims to answer are:

1. What are the rates of compliance with and reasons for discontinuation of adjuvant OFS endocrine therapy?
2. What is the impact of OFS treatment duration on patient prognosis?

Participants, who are already receiving OFS treatment as part of their regular medical care, will have their demographic data, treatment status, clinical outcomes, and adverse events collected over time.

Conditions

  • Breast Cancer Females

Sponsors & Collaborators

  • Beijing Health Promotion Association

    collaborator UNKNOWN

  • Zhejiang Cancer Hospital

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-10
Primary Completion
2029-07-31
Completion
2029-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07180914 on ClinicalTrials.gov